5 completed, 4 recruiting, 1 unknown. 10 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 5, Recruiting 4, Unknown 1 |
| Phase 3 | 3 | Completed 2, Unknown 1 |
Follow Atorvastatin 20mg: new trials by email Literature Review of Atorvastatin 20mg trials Research Report on Atorvastatin 20mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prophylactic Treatment With Atorvastatin for Episodic Migraine. Atorvastatin 40mg, Placebo, Atorvastatin 20mg - Episodic Migraine | Phase 2 | Recruiting | St. Olavs Hospital | 450 | 2024-05-01 | 2026-07-14 |
| Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma Atorvastatin 20mg - Glioblastoma, IDH-wildtype | Phase 2 | Recruiting | Tianjin Medical University General Hospital | 50 | 2024-04-01 | 2024-03-25 |
| ATORvastatin in Pulmonary TUBerculosis Atorvastatin 20mg, Atorvastatin 40mg, Atorvastatin 60mg - Pulmonary Tuberculosis, Tuberculosis | Phase 2 | Recruiting | Obafemi Awolowo University Teaching Hospital | 440 | 2024-01-03 | 2025-09-25 |
| Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk Atorvastatin 20mg, Placebo - Liver Fibroses, Cirrhosis | Phase 2 | Recruiting | Raymond Chung | 60 | 2023-05-10 | 2026-10-07 |
| Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis Allopurinol 300 MG, Atorvastatin 20mg, Placebo - Cirrhosis, Hepatic Encephalopathy | Phase 2 / Phase 3 | Completed | Tanta University | 150 | 2022-11-15 | 2026-08-11 |
| Statin Impact on Hepatic Decompensation Atorvastatin 20mg, Placebo - Quality of Life, the Incidence of Whole Complications Resultant From Decompensated Liver | Phase 2 / Phase 3 | Completed | Tanta University | 100 | 2022-06-15 | 2026-09-14 |
| Atorvastatin in Management of Newly Diagnosed ITP Atorvastatin 20mg, Atorvastatin 10mg, Dexamethasone - Immune Thrombocytopenia, Purpura, Thrombocytopenic | Phase 2 / Phase 3 | Unknown | Shandong University | 30 | 2021-11-01 | 2021-09-05 |
| To Assess the Safety, Efficacy and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors Atorvastatin 20mg, Atorvastatin 20 mg + CKD-519 50 mg, Atorvastatin 20 mg + CKD-519 100 mg - Dyslipidemias | Phase 2 | Completed | Chong Kun Dang Pharmaceutical | 62 | 2017-03-23 | 2018-11-06 |
| Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C Bempedoic acid 180mg, Ezetimibe 10mg, Atorvastatin 20mg - Hypercholesterolemia | Phase 2 | Completed | Esperion Therapeutics, Inc. | 63 | 2017-01-19 | 2020-04-03 |
| Impact of Adjuvant Statin Therapy in Patients Who Underwent Radical Prostatectomy for Locally Advanced Prostate Cancer Atorvastatin 20mg - Prostatic Neoplasms | Phase 2 | Completed | Asan Medical Center | 364 | 2012-10-01 | 2022-01-25 |
Fibrosis (2) · Ascites (1) · Dyslipidemias (1) · Glioblastoma (1) · Hepatic Encephalopathy (1) · Hepatorenal Syndrome (1) · Hypercholesterolemia (1) · Hyperlipidemias (1) · Liver Cirrhosis (1) · Liver Diseases (1) · Migraine Disorders (1) · Prostatic Neoplasms (1) · Purpura, Thrombocytopenic (1) · Purpura, Thrombocytopenic, Idiopathic (1) · Tuberculosis (1)
Tanta University (2) · Asan Medical Center (1) · Chong Kun Dang Pharmaceutical (1) · Esperion Therapeutics, Inc. (1) · Obafemi Awolowo University Teaching Hospital (1) · Raymond Chung (1) · Shandong University (1) · St. Olavs Hospital (1) · Tianjin Medical University General Hospital (1)
China (2) · Egypt (2) · United States (2) · Australia (1) · Nigeria (1) · Norway (1) · South Korea (1)
Anne H Aamodt, Senior researcher (1) · Bendik S Winsvold, Post.doc. (1) · Bolanle A Omotoso, MD (1) · Choung-Soo Kim, MD (1) · Chunsheng Kang (1) · Kjersti G Vetvik, Ph.d. (1) · Kyung-Mi Park, PhD (1) · Linn H Steffensen, Associate Professor II (1) · Ming Hou, Dr (1) · Olanisun O Adewole, MD (1) · Raymond Chung, MD (1) · Ron Haberman, MD (1)